Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas
14 Setembro 2023 - 5:05PM
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by abnormally elevated aldosterone, today announced the
appointments of Daphne Karydas and Glenn Sblendorio to its Board of
Directors (the Board). Ms. Karydas and Mr. Sblendorio bring
executive, financial and operational leadership experience in
biotechnology and biopharmaceuticals markets. In addition,
Mineralys announced that Takeshi Takahashi of Catalys Pacific has
stepped down from the Board, effective September 12, 2023.
“We are excited to have Daphne and Glenn join our Board and
support Mineralys' efforts to develop innovative medicines aimed to
improve the lives of patients with cardiorenal disorders. They both
bring extensive experience to Mineralys as respected executive
leaders in the life sciences industry and their significant insight
into the financial markets, which we expect to complement our
current Board,” said BT Slingsby, M.D., Ph.D.,M.P.H., Founder and
Executive Chair of Mineralys and Founder of Catalys Pacific. “The
Board and I greatly appreciate Takeshi’s guidance and contributions
to the launch and growth of Mineralys.”
Ms. Karydas currently serves as President and Chief Financial
Officer of Flare Therapeutics Inc. where she has been since October
2021. Prior to Flare Therapeutics, she served as the Chief
Financial Officer of Syndax Pharmaceuticals Inc. from July 2020 to
October 2021. From April 2017 to May 2020, Ms. Karydas held several
roles at Allergan plc, including Senior Vice President of Corporate
Strategy and Financial Planning & Analysis. Prior to her senior
executive and top manager roles at these biotech and pharmaceutical
companies, Ms. Karydas spent more than 15 years in investment
banking and asset management roles that focused exclusively on the
healthcare space, including biopharmaceuticals, life sciences and
medical technologies. Ms. Karydas has previously served on the
boards of directors at Elicio Therapeutics, LogicBio Therapeutics,
Inc., and Eucrates Biomedical Acquisition Corp. Ms. Karydas
received a B.A. and M.S. in chemical engineering from the
Massachusetts Institute of Technology and an M.B.A. from Harvard
Business School.
Mr. Sblendorio was Chief Executive Officer and a member of the
board of directors of IVERIC bio, Inc., a publicly-held
biotechnology company, from July 2017 until it was acquired by
Astellas Pharma in July of 2023. Prior to IVERIC, Mr. Sblendorio
was President and Chief Financial Officer of The Medicines Company
from March 2006 through March 2016 and was a member of the board of
directors of The Medicines Company from July 2011 through December
31, 2015. Before joining The Medicines Company, Mr. Sblendorio was
Executive Vice President and Chief Financial Officer of Eyetech
Pharmaceuticals, Inc. from February 2002 until it was acquired by
OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also
served as a Managing Director of MPM Capital Advisors from 1998
through 2000. Mr. Sblendorio also serves as a member of the board
of directors of Intercept Pharmaceuticals, Inc. and as a member of
the board of directors of Amicus Therapeutics, Inc. Mr. Sblendorio
received his B.B.A. from Pace University and his M.B.A. from
Fairleigh Dickinson University and is a graduate of the Harvard
Advanced Management Program.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, CKD and other
diseases driven by abnormally elevated aldosterone. Its initial
product candidate, lorundrostat, is a proprietary, orally
administered, highly selective aldosterone synthase inhibitor that
Mineralys Therapeutics is developing for cardiorenal conditions
affected by abnormally elevated aldosterone, including hypertension
and CKD. Mineralys is based in Radnor, Pennsylvania, and was
founded by Catalys Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Photos accompanying this announcement are available
at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/932bf951-78fd-4828-ba7c-91b98cf62b79
https://www.globenewswire.com/NewsRoom/AttachmentNg/d13b3d59-ff60-424b-8065-fc1f961c2252
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024